KAS
ARQT icon

Kestra Advisory Services’s Arcutis Biotherapeutics ARQT Stock Holding History

Kestra Advisory Services’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$209K Sell
8,886
-560
-6% -$14.3K ﹤0.01% 2918
2025
Q4 		$274K Sell
9,446
-674
-7% -$17.3K ﹤0.01% 2616
2025
Q3 		$191K Sell
10,120
-1,430
-12% -$22.6K ﹤0.01% 2752
2025
Q2 		$162K Buy
+11,550
New +$162K ﹤0.01% 2686

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kestra Advisory Services's ARQT Position: Q1 2026 in Review

Kestra Advisory Services reduced its Arcutis Biotherapeutics (ARQT) stake by 5.9% in Q1 2026, selling an estimated $14.3K and leaving 8,886 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #2918.

Kestra Advisory Services first reported a position in ARQT in Q2 2025 and has held it in 4 quarters since. The position peaked at $274K in Q4 2025. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Kestra Advisory Services held 8,886 shares of Arcutis Biotherapeutics worth $209K as of Q1 2026.
  • Kestra Advisory Services sold 560 Arcutis Biotherapeutics shares in Q1 2026, an estimated $14.3K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q1 2026, its #2918 holding.
  • Kestra Advisory Services first reported a position in Arcutis Biotherapeutics in Q2 2025 and has held it in 4 quarters since.
  • Kestra Advisory Services's Arcutis Biotherapeutics position peaked at $274K in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.